Skip to content

Emergent Biosolutions EBS Income Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$676.8M-29.9%$742.9M-28.8%$788.9M-29.9%$851.6M-22.7%$965.4M-18.6%
$309.7M-50.5%$326.2M-52.1%$359.3M-52.0%$396M-50.7%$625.2M-10.3%
$367.1M+7.9%$416.7M+15.0%$429.6M+13.9%$455.6M+52.1%$340.2M-30.3%
54.2%+19.0pp56.1%+21.4pp54.5%+21.0pp53.5%+26.3pp35.2%-6.0pp
$48.6M-31.3%$53.2M-24.8%$50.2M-44.8%$50.5M-45.4%$70.7M-17.6%
$180.3M-34.6%$186.1M-39.6%$195.8M-41.9%$233.5M-32.6%$275.7M-21.6%
$65.3M+0.2%$65.1M0.0%$65.1M+0.2%$65.1M+0.2%$65.2M+0.6%
$616.1M-42.1%$642.8M-44.2%$670.4M-47.2%$745.1M-52.0%$1.06B-38.3%
$118.5M+183%$106.5M+124%-$98.6M+81.7%
$55.6M-9.4%$59.3M-16.5%$59.4M-23.7%$52.5M-41.2%$61.4M-34.9%
-$57.2M-258%-$17.3M+49.4%-$12.6M+53.0%$84.2M+166%$36.3M+286%
$12.2M+0.8%$0-100%-$12.2M$52.1M$12.1M
$105.9M+162%$190.7M+133%-$62.3M+88.8%
$12.1M-82.5%$30.2M-36.7%$30M$51.2M$69.3M
$75.9M+136%$139.5M+124%-$131.6M+76.7%
$1.31+133%$2.46+122%-$2.70+75.3%
$1.42+136%$2.62+123%-$2.54+76.8%
223.9M+2.5%224.7M+5.3%221M+4.4%220.1M+5.9%218.5M+6.1%
212.8M-0.1%215.3M+2.1%214.8M+2.7%214.7M+3.3%213.1M+3.5%
$65.3M+0.2%$65.1M0.0%$65.1M+0.2%$65.1M+0.2%$65.2M+0.6%
$676.8M-29.9%$742.9M-28.8%$788.9M-29.0%$851.6M-21.1%$965.4M-11.2%
$118.5M+183%$106.5M+124%-$98.6M+81.7%
$216.8M+808%$207.8M+162%$7.7M+102%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What is Emergent Biosolutions's revenue?
Emergent Biosolutions (EBS) generated $676.8M in revenue over the trailing twelve months, down 29.9% year over year.
Is Emergent Biosolutions profitable?
Emergent Biosolutions reported $114.0M in net income over the trailing twelve months, a 9.6% net margin.
What are Emergent Biosolutions's profit margins?
Gross margin is 54.2% and operating margin is 15.0%, with a 9.6% net margin.
What is Emergent Biosolutions's earnings per share?
Emergent Biosolutions's diluted EPS over the trailing twelve months is $1.95.
Where does Emergent Biosolutions's income statement data come from?
Every line is extracted from Emergent Biosolutions's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.